Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKEs) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis

Trial Profile

CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKEs) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs OXS-3550 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Mastocytosis; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 06 Feb 2019 According to a GT Biopharma media release, the company expects to initiate this trial in the first half of 2019. The study will be led by Principal Investigator, Erica Warlick, Associate Professor, Division of Hematology, Oncology and Transplantation at Masonic Cancer Center, University of Minnesota.
    • 06 Feb 2019 According to a GT Biopharma media release, an nvestigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now open and the company is authorized to initiate a first-in-human phase I study.
    • 16 Jan 2019 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top